Our compound library consists of four sub-libraries, forming a highly chemically diverse collection. In addition, subsets of known drugs and reference compounds (approximately 1200) that can be used for drug-repurposing studies and assay validation complement our library. 4 Sub-Libraries include both 309.450 unique compounds with 184.355 unique substructures and 22.873 unique scaffolds, and most if not all are Lipinksi’s rule of 5 compliant.
Our library is extensively validated during procurement by our in-house medicinal chemists and widely employed by for instance research institutions, biotech and pharmaceutical companies during their early drug discovery projects.
Pivot Park Screening Centre not only has its own library of over 300,000 high-quality drug-like compounds, but also offers you the capability to bring your own library or request specific vendor sets. Pivot Park Screening Centre handles libraries of several millions of compounds per screen, allowing a tailored approach to your ultra High Throughput Screening Project. In other words, giving you the greatest coverage of chemical space to maximize the chance of finding hits. We can store your library in our facility: ready for use by our robots.
An additional advantage of performing your screen at Pivot Park Screening Centre is that as a partner in the European Lead Factory (ELF), we have access to the unique ELF compound library of >0.5 million compounds.
For diversity reasons, you want as many different scaffolds as possible, so a frequency of 1 for each scaffold. But from an operational perspective you like to see several hits from the same series because that gives you an idea of structure activity relationships (SAR). We have tried to find a good balance: so as much diversity as possible, but also recurring scaffolds for SAR.
Although our high-quality library meets the Lipinski rule of 5 for 86%, we always advise to keep these rules as guidelines. Exploring the boundaries of drug-like space may help to find hits for challenging targets.
The drug-likeness of our library follows from the distributions of a range of molecular properties and from an analysis of the diversity space of known hits and leads in drug discovery.
It is crucial to apply high standards for compound management to ensure that the physical quality of the compounds remains at a high level. For this reason we apply the REMP tube technology for compound management.
The quality of our compound library is not only validated by ourselves but also by several of our customers. To maintain this quality, compound management is key!
Combining the access to these compound libraries with our longstanding and proven experience gained during the most diverse screens, our team of scientists know exactly how to make the most of your screening campaign.
130K Historical collection.
A set of compounds inherited from Organon/MSD when PPSC was established. This set contains screening molecules which were carefully selected using cheminformatics tools.
87K acquired in 2012.
This set was selected by PPSC, from commercial vendors, to increase the diversity of the historical collection. The latest insights in desired molecular properties were applied. About 70% of this set was examined by experienced medicinal chemists to ensure tractable compounds were included in this set.
8K pharma origin.
Compounds synthesised at Organon/MSD
70K BioAscent extension.
This is a subset of the collection of the Scottish company BioAscent. It adds further diversity to the above sets.
PPSC has extensive knowledge of screening customers’ libraries. As a result of its experience in the European Lead Factory, it is a front-runner in screening shared libraries.
PPSC offers a new solution for screening compound libraries that are shared among partners, and provides cost-effective access to a larger chemical space.